H. Lundbeck, Cephalon and Lundbeck announce discontinuation of CEP-1347 clinical trial in Parkinson’s disease

Cephalon, Inc. and H. Lundbeck A/S announced today the discontinuation of their Phase 2/3 clinical trial of CEP-1347 in Parkinson’s disease. An independent data monitoring committee just completed a planned review of interim results and concluded that the data are unlikely to provide evidence of significant effect. There were no safety concerns.